Agents that target the TH17-interleukin pathway show promise in psoriatic arthritis, as alternatives for patients who don't benefit from TNFα blockers. This slide show describes their mode of action and potential.
Prolonged Medical Fasting May Benefit Pain Symptoms in Fibromyalgia
Emerging Agents in the Treatment of Rheumatic Diseases
MRI Treat-to-Target Strategy Fails to Help RA Patients Reach Remission
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
International Working Group Releases First Guideline for Osteoporosis in Men
Deucravacitinib Improves Patient-Reported Outcomes in Active Psoriatic Arthritis